| abstract |
Disclosed in the present invention are a CLDN18.2-targeting antibody or an antigen binding fragment thereof and the use thereof. The antibody or the antigen binding fragment thereof contains a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains HCDR1, HCDR2 and HCDR3; the light chain variable region contains LCDR1, LCDR2 and LCDR3; and the sequence information thereof is shown in detail in the present invention. The binding capacity of the antibody prepared in the present invention with cells such as hCLDN18.2-HEK293T cells and hCLDN18.2-KATOIII cells is equivalent to or better than that of a control antibody IMAB362; and the effects of ADCC, CDC and the like of the antibody on hCLDN18.2-KATOIII cells, hCLDN18.2-HEK293T cells or hCLDN18.2-HEK293 cells are significantly superior to those of the control antibody IMAB362. |